Acceleron Pharma, a Cambridge, MA-based maker of genetically engineered drugs for treating conditions such as anemia and bone loss, has pulled in $8.4 million of a planned $11.5 million offering of equity, options, and warrants, according to an SEC filing. Members of Advanced Technology Ventures, Venrock Associates, Flagship Ventures, OrbiMed Advisors, and Polaris Venture Partners are among those listed as Acceleron directors on the filing for the newest funding. Alkermes CEO Richard Pops is also listed as a member of the Acceleron board. Luke wrote about Acceleron back in December when the company gave him a tour of its Cambridge facilities, after it had invested in building its own manufacturing and development site rather than outsourcing the tasks.
Author: Erin Kutz
Erin Kutz has a background in covering business, politics and general news. She holds a bachelor’s degree in journalism from Boston University. Erin previously worked in the Boston bureau of Reuters, where she wrote articles on the investment management and mutual fund industries. While in college, she researched for USA Today reporter Jayne O’Donnell’s book, Gen Buy: How Tweens, Teens and Twenty-Somethings Are Revolutionizing Retail. She also spent a semester in Washington, DC, reporting Capitol Hill stories as a correspondent for two Connecticut newspapers and interning in the Money section of USA Today, where she assisted with coverage on the retail and small business beats. Erin got her first taste of reporting at Boston University’s independent student newspaper, as a city section reporter and fact checker and editor of the paper’s weekly business section.
View all posts by Erin Kutz
